Lumos Non Current Liabilities Total vs Non Currrent Assets Other Analysis
| LUMO Stock | USD 4.30 0.02 0.46% |
Lumos Pharma financial indicator trend analysis is infinitely more than just investigating Lumos Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lumos Pharma is a good investment. Please check the relationship between Lumos Pharma Non Current Liabilities Total and its Non Currrent Assets Other accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.
Non Current Liabilities Total vs Non Currrent Assets Other
Non Current Liabilities Total vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lumos Pharma Non Current Liabilities Total account and Non Currrent Assets Other. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Lumos Pharma's Non Current Liabilities Total and Non Currrent Assets Other is 0.18. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Lumos Pharma, assuming nothing else is changed. The correlation between historical values of Lumos Pharma's Non Current Liabilities Total and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Lumos Pharma are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Non Current Liabilities Total i.e., Lumos Pharma's Non Current Liabilities Total and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | 0.18 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Non Current Liabilities Total
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most indicators from Lumos Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lumos Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.At this time, Lumos Pharma's Selling General Administrative is very stable compared to the past year. As of the 28th of November 2024, Issuance Of Capital Stock is likely to grow to about 761.2 K, while Tax Provision is likely to drop (44.1 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 484K | 874K | 1.0M | 671.3K | Depreciation And Amortization | 203K | 49K | 44K | 41.8K |
Lumos Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Lumos Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lumos Pharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 96.8M | 129.0M | 100.3M | 72.3M | 40.6M | 38.6M | |
| Short Long Term Debt Total | 1.2M | 319K | 557K | 233K | 585K | 555.8K | |
| Other Current Liab | 10.2M | 5.6M | 3.8M | 6.0M | 5.6M | 5.8M | |
| Total Current Liabilities | 11.8M | 6.5M | 5.1M | 6.7M | 7.0M | 11.8M | |
| Total Stockholder Equity | 78.9M | 116.6M | 89.0M | 59.6M | 27.3M | 25.9M | |
| Property Plant And Equipment Net | 2.4M | 584K | 635K | 283K | 603K | 572.9K | |
| Net Debt | (89.3M) | (98.4M) | (94.3M) | (55.8M) | (34.5M) | (36.2M) | |
| Retained Earnings | (334.0M) | (66.0M) | (96.4M) | (127.5M) | (161.5M) | (169.6M) | |
| Accounts Payable | 475K | 244K | 612K | 275K | 890K | 845.5K | |
| Cash | 90.5M | 98.7M | 94.8M | 56.0M | 35.1M | 33.3M | |
| Non Current Assets Total | 2.4M | 584K | 635K | 283K | 603K | 572.9K | |
| Non Currrent Assets Other | 735K | (584K) | (635K) | (283K) | (325.5K) | (341.7K) | |
| Cash And Short Term Investments | 90.5M | 98.7M | 94.8M | 67.4M | 36.1M | 34.3M | |
| Net Receivables | 824K | 26.3M | 128K | 223K | 210K | 199.5K | |
| Common Stock Total Equity | 372K | 373K | 12K | 83K | 74.7K | 71.0K | |
| Common Stock Shares Outstanding | 144.7K | 6.8M | 8.3M | 8.4M | 8.1M | 4.1M | |
| Liabilities And Stockholders Equity | 96.8M | 129.0M | 100.3M | 72.3M | 40.6M | 38.6M | |
| Non Current Liabilities Total | 6.9M | 6.1M | 6M | 6.2M | 6.3M | 6.0M | |
| Other Current Assets | 3.0M | 3.5M | 4.7M | 4.4M | 3.7M | 6.2M | |
| Other Stockholder Equity | 412.5M | 311.5M | 185.3M | 187.0M | 188.7M | 223.2M | |
| Total Liab | 17.9M | 12.5M | 11.3M | 12.7M | 13.3M | 21.4M | |
| Property Plant And Equipment Gross | 457K | 584K | 635K | 283K | 603K | 572.9K | |
| Total Current Assets | 94.4M | 128.4M | 99.7M | 72.0M | 40.0M | 38.0M | |
| Accumulated Other Comprehensive Income | (6.6M) | (7.0M) | (63.5M) | (129.0M) | 0.0 | (9K) | |
| Short Term Debt | 1.1M | 638K | 704K | 466K | 564K | 579.2K | |
| Common Stock | 373K | 374K | 83K | 82K | 81K | 77.0K | |
| Net Tangible Assets | 78.9M | 116.6M | 89.0M | 59.6M | 68.5M | 104.9M | |
| Retained Earnings Total Equity | (237.5M) | (291.0M) | (334.0M) | (66.0M) | (59.4M) | (62.4M) | |
| Capital Surpluse | 389.8M | 407.2M | 414.0M | 182.5M | 209.9M | 293.4M | |
| Property Plant Equipment | 1.6M | 335K | 635K | 283K | 254.7K | 242.0K |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.